(1) In accordance with M.G.L. c. 112, § 24B1/2, subsection (b), to qualify to enter into a collaborative practice agreement and engage in collaborative practice, a pharmacist must:
(a) hold a current unrestricted license in good standing to practice pharmacy in the Commonwealth and currently be engaged in pharmacy practice in the Commonwealth;
(b) maintain at least $1,000,000 (per occurrence) of professional liability insurance during the term of the agreement which specifically covers drug therapy management;
(c) have completed five years of experience as a licensed pharmacist or have satisfied one of the requirements in 247 CMR 16.02(1)(c)1. through 2.:
1. have earned a doctor of pharmacy degree and have entered into a collaborative practice agreement on or before June 30, 2017; or
2. have completed such other education or residency criteria that the Board determines to be the equivalent of five years experience as a licensed pharmacist;
(d) devote a portion of practice to the defined drug therapy area that the pharmacist shall co-manage;
(e) complete, in each year of the term of the agreement, at least five additional contact hours of Board-approved continuing education that address areas of practice generally related to the particular collaborative practice agreement; and
(f) if prescriptive practices are included in the collaborative practice agreement:
1. maintain a current controlled substance registration issued by the Department during the term of the agreement, pursuant to M.G.L. c. 94C, §§ 7 and 9 and 105 CMR 700.000: Implementation of M.G.L. c. 94C.
2. complete training required pursuant to M.G.L. c. 94C, § 18(e) prior to initially obtaining a controlled substance registration and at least biennially thereafter as a condition precedent to renewing his or her pharmacist license;
3. submit an attestation, signed under the pains and penalties of perjury, that the pharmacist participates in, or had applied to participate in, MassHealth as either a provider of services or for the limited purpose of ordering and referring services covered by MassHealth, in accordance with M.G.L. c. 112, § 24B1/2.
(2) An authorized pharmacist participating in CDTM must maintain evidence of completion of required continuing education for at least two years after the date of the current collaborative practice agreement.
(3) Whenever an authorized pharmacist participating in CDTM is disciplined by the Board, whether by agreement or Board order, or otherwise subject to any practice restrictions, the authorized pharmacist must provide written notification of such discipline or practice restriction to each supervising physician.
